Lung Cancer Liquid Biopsy Market Size & Growth Forecast 2027–2036, By Segments (Sample Type, Technology, Product, Biomarker, End-use, Clinical Application), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape
Market Size and Growth Outlook
Lung Cancer Liquid Biopsy Market size stood at USD 1.39 billion in 2026 and is predicted to grow at a 12.64% CAGR from 2027 to 2036, exceeding USD 4.57 billion by 2036. The industry revenue for 2027 is assessed at USD 1.54 billion.
Get more details on this report
Request Free Sample ReportLung Cancer Liquid Biopsy Market Intelligence Snapshot
Regional Market Dynamics
- North America accounted for 53.00% of the market in 2026, supported by advanced molecular diagnostics infrastructure, widespread biomarker testing, and established oncology care pathways.
- Asia Pacific is projected to grow at a 14.67% CAGR as healthcare systems expand molecular diagnostics, precision oncology adoption increases, and demand rises for less invasive cancer testing.
Segment Momentum
- Blood sample-based testing held a 67.9% market share in 2026 because it enables routine, repeat monitoring through simple collection, supporting timely molecular assessment and broader clinical adoption with less procedural burden.
- Multi-gene-parallel Analysis (NGS) is growing fastest because it delivers comprehensive genomic profiling from a single sample, improving testing efficiency and supporting therapy selection and ongoing disease management.
Market Expansion Drivers
- Rising global lung cancer prevalence driving demand for early non-invasive diagnostic testing.
- Increasing FDA approvals and companion diagnostics accelerating clinical adoption of liquid biopsy.
- Expanding oncology precision medicine programs improving biomarker-based treatment selection.
Leading Market Participants
- Leading players in the lung cancer liquid biopsy market include F. Hoffmann-La Roche Ltd. (Switzerland), Guardant Health, Inc. (United States), Illumina, Inc. (United States), Thermo Fisher Scientific Inc. (United States), QIAGEN N.V. (Netherlands), Exact Sciences Corporation (United States), Natera, Inc. (United States), Agilent Technologies, Inc. (United States), Bio-Rad Laboratories, Inc. (United States), Myriad Genetics, Inc. (United States).
Global Market Forecast Snapshot
Market Outlook
- 2026 Market Size: USD 1.39 billion
- 2027 Estimated Market Size: USD 1.54 billion.
- Projected Market Size: USD 4.57 billion by 2036
- Growth Forecast: 12.64% CAGR (2027-2036)
Regional and Segment Outlook
- Leading Regional Market: North America
- High-Growth Regional Hub: Asia Pacific
- Core Revenue Segment: Blood Sample Based (Sample Type) | Multi-gene-parallel Analysis (NGS) (Technology) | Consumables Kits and Reagents (Product) | Circulating Nucleic Acids (Biomarker) | Hospitals & Laboratories (End-use) | Therapy Selection (Clinical Application)
- Emerging Opportunity Segment: Blood Sample Based (Sample Type) | Multi-gene-parallel Analysis (NGS) (Technology) | Instruments (Product) | Exosomes/Microvesicles (Biomarker) | Specialty Clinics (End-use) | Early Cancer Screening (Clinical Application)
Market Growth Drivers and Industry Trends
Rising global lung cancer prevalence driving demand for early non-invasive diagnostic testing
The growing burden of lung cancer is increasing the need for accessible diagnostic approaches capable of identifying disease-related biomarkers with less patient burden than conventional tissue sampling. The lung cancer liquid biopsy market is supported by the use of blood-based testing to detect circulating tumor DNA and other molecular indicators that can provide clinically relevant information without requiring invasive tissue collection in every testing scenario. Liquid biopsy can also facilitate repeated testing during disease assessment, making it useful when monitoring molecular changes or when obtaining tissue samples is difficult. Increasing emphasis on earlier cancer detection and more individualized diagnostic pathways is encouraging healthcare providers to consider non-invasive biomarker-based approaches alongside established diagnostic methods.
Increasing FDA approvals and companion diagnostics accelerating clinical adoption of liquid biopsy
Regulatory clearances and the growing development of companion diagnostic applications are strengthening confidence in liquid biopsy as a clinically relevant tool for oncology decision-making. The lung cancer liquid biopsy market gains from regulatory recognition because approved diagnostic applications can support integration into clinical workflows and provide healthcare professionals with clearer pathways for using molecular test results. Companion diagnostics can also connect biomarker detection with treatment selection by identifying molecular characteristics relevant to targeted therapies, particularly when tissue availability is limited or additional molecular information is required. As regulatory frameworks and clinical validation continue to support these applications, healthcare institutions have greater incentives to incorporate liquid biopsy into precision oncology practices.
Expanding oncology precision medicine programs improving biomarker-based treatment selection
Expansion of precision medicine initiatives is increasing the importance of molecular profiling in lung cancer treatment, creating demand for diagnostic technologies capable of identifying actionable biomarkers. In the lung cancer liquid biopsy market, blood-based molecular analysis can complement tissue testing by providing information on tumor-related genetic alterations that may guide selection of targeted therapies. Liquid biopsy can also be useful when tumor tissue is insufficient, difficult to obtain, or unsuitable for repeated molecular assessment, allowing clinicians to evaluate circulating biomarkers through a less invasive approach. Broader adoption of personalized oncology programs is therefore increasing the role of biomarker testing in treatment planning, disease monitoring, and therapeutic decision-making.
| Growth Driver | Impact on CAGR | Regulatory Influence | Geographic Relevance | Adoption Rate | Impact Timeline |
|---|---|---|---|---|---|
| Rising global lung cancer prevalence driving demand for early non-invasive diagnostic testing | 2.40% | High | North America, Asia Pacific | High | Near Term |
| Increasing FDA approvals and companion diagnostics accelerating clinical adoption of liquid biopsy | 2.00% | High | North America, Europe | High | Near Term |
| Expanding oncology precision medicine programs improving biomarker-based treatment selection | 1.80% | High | North America, Asia Pacific | Medium | Mid Term |
Unlock insights tailored to your business with our bespoke market research solutions.
Click to get your customized report now.
Regional Demand Dynamics
North America (Largest Region)
The lung cancer liquid biopsy market was led by North America, which accounted for a 53.00% share in 2026, supported by advanced oncology infrastructure, strong adoption of precision medicine, and established capabilities in molecular diagnostics. Healthcare providers are increasingly using minimally invasive approaches to obtain clinically relevant information for cancer detection, treatment selection, and disease monitoring. The region's emphasis on personalized care and integration of molecular testing into oncology workflows is supporting demand for liquid biopsy technologies. Continued investment in cancer research, diagnostic innovation, and advanced laboratory infrastructure further strengthens the regional market position.
Asia Pacific (Fastest-Growing Region)
Asia Pacific represents the fastest-growing region, supported by expanding oncology services, improving diagnostic infrastructure, and increasing awareness of early cancer detection. Healthcare systems are progressively adopting advanced molecular diagnostic approaches as demand for more accessible and less invasive testing increases. Growing investment in laboratory capabilities and precision medicine is creating opportunities for liquid biopsy technologies across the region. The rising focus on personalized cancer treatment and improved diagnostic access is further encouraging adoption of liquid biopsy solutions for lung cancer management.
| Parameter | North America | Asia Pacific | Europe | Latin America | MEA |
|---|---|---|---|---|---|
| Innovation Hub i Scale Nascent Developing Advanced | |||||
| Cost-Sensitive Region i Scale Low Medium High | |||||
| Regulatory Environment i Scale Restrictive Neutral Supportive | |||||
| Demand Drivers i Scale Weak Moderate Strong | |||||
| Development Stage i Scale Emerging Developing Developed | |||||
| Adoption Rate i Scale Low Medium High | |||||
| New Entrants / Startups i Scale Sparse Moderate Dense | |||||
| Macro Indicators i Scale Weak Stable Strong |
Key Country Insights
Germany 🇩🇪
Molecular Diagnostics FocusGermany is strengthening lung cancer liquid biopsy adoption through investments in advanced molecular diagnostics and precision medicine. Clinical laboratories are emphasizing standardized testing workflows that improve biomarker identification and treatment selection.
France 🇫🇷
Personalized Cancer DiagnosticsFrance is encouraging broader adoption of lung cancer liquid biopsy within precision medicine initiatives. Clinical centers focus on improving access to minimally invasive genomic testing that supports individualized therapeutic decision-making for oncology patients.
Italy 🇮🇹
Oncology Testing ModernizationItaly is modernizing lung cancer diagnostics by incorporating liquid biopsy into oncology care pathways where clinically appropriate. Healthcare providers emphasize faster molecular insights that complement conventional diagnostic methods and support personalized treatment strategies.
Japan 🇯🇵
Biomarker Testing IntegrationJapan is incorporating lung cancer liquid biopsy into oncology care to improve genomic testing efficiency and patient management. Healthcare institutions prioritize accurate biomarker detection that supports targeted therapies while reducing dependence on invasive procedures.
South Korea 🇰🇷
Clinical Genomics ExpansionSouth Korea is increasing the clinical use of lung cancer liquid biopsy to enhance precision oncology programs and genomic profiling capabilities. Hospitals are integrating advanced molecular testing technologies to improve treatment planning and patient monitoring.
United States 🇺🇸
Precision Oncology AdoptionThe U.S. is expanding the use of lung cancer liquid biopsy technologies to support earlier molecular profiling and personalized treatment decisions. Healthcare providers increasingly integrate liquid biopsy into clinical workflows to complement tissue-based diagnostic approaches.
Segment Leadership and Growth Trends
Lung Cancer Liquid Biopsy Market Share (%), by Sample Type, 2026
Go beyond the chart, access full insights & data tables
Request Free Sample ReportSample Type Segment Analysis: Blood Sample Based (Largest & Fastest-Growing Segment)
The blood sample based segment dominated the lung cancer liquid biopsy market in 2026, accounting for a 67.9% share, supported by its minimally invasive nature, ease of collection, and suitability for repeated testing during disease monitoring. Blood-based liquid biopsy enables clinicians to obtain circulating tumor DNA and other biomarkers without the procedural burden associated with tissue biopsies, making it particularly valuable for patients who may have limited or inaccessible tumor tissue. Its broader clinical practicality also supports applications in treatment selection, molecular profiling, and monitoring of tumor response, strengthening adoption across lung cancer care pathways. As precision oncology increasingly emphasizes less invasive and repeatable diagnostic approaches, the segment is also positioned as the fastest-growing within the sample type category.
Technology Segment Analysis: Multi-gene-parallel Analysis (NGS) (Largest & Fastest-Growing Segment)
The multi-gene-parallel analysis (NGS) segment held the largest share of the lung cancer liquid biopsy market in 2026 and is also expected to register the fastest growth, reflecting the increasing importance of comprehensive molecular profiling in lung cancer diagnosis and treatment planning. NGS can evaluate multiple genetic alterations simultaneously from liquid biopsy samples, allowing clinicians to identify actionable biomarkers while reducing the need for sequential testing. Its ability to support broader genomic characterization is particularly relevant as targeted therapies and biomarker-driven treatment strategies become more integral to lung cancer management. Continued advances in sequencing capabilities and the growing clinical emphasis on precision medicine are reinforcing the role of multi-gene-parallel analysis as a key technology within liquid biopsy workflows.
| Segment | Sub-Segment | Largest Segment | Fastest Growing |
|---|---|---|---|
| Sample Type | Blood Sample Based, Others | Blood Sample Based | Blood Sample Based |
| Technology | Multi-gene-parallel Analysis (NGS), Single Gene Analysis (PCR Microarrays) | Multi-gene-parallel Analysis (NGS) | Multi-gene-parallel Analysis (NGS) |
| Product | Instruments, Consumables Kits and Reagents, Software and Services | Consumables Kits and Reagents | Instruments |
| Biomarker | Circulating Nucleic Acids, CTC, Exosomes/Microvesicles, Circulating Proteins | Circulating Nucleic Acids | Exosomes/Microvesicles |
| End-use | Hospitals & Laboratories, Specialty Clinics, Academic & Research Centers, Others | Hospitals & Laboratories | Specialty Clinics |
| Clinical Application | Therapy Selection, Treatment Monitoring, Early Cancer Screening, Recurrence Monitoring, Others | Therapy Selection | Early Cancer Screening |
Competitive Landscape and Market Positioning
Key companies in the lung cancer liquid biopsy market:
1. F. Hoffmann-La Roche Ltd. (Switzerland)
2. Guardant Health Inc. (United States)
3. Illumina Inc. (United States)
4. Thermo Fisher Scientific Inc. (United States)
5. QIAGEN N.V. (Netherlands)
6. Exact Sciences Corporation (United States)
7. Natera Inc. (United States)
8. Agilent Technologies Inc. (United States)
9. Bio-Rad Laboratories Inc. (United States)
10. Myriad Genetics Inc. (United States)
The lung cancer liquid biopsy market is progressing through advancements in non-invasive diagnostic techniques. Improved molecular detection methods are enabling earlier and more accurate diagnosis. Collaborative research efforts are accelerating clinical adoption. The lung cancer liquid biopsy market is reshaping oncology diagnostics through precision testing approaches.
| Company | Market Share | Company Revenue | Revenue CAGR (%) | Product Portfolio | Geographic Presence | Innovation / R&D Focus | Strategic Developments |
|---|---|---|---|---|---|---|---|
| F. Hoffmann-La Roche Ltd. (Switzerland) | |||||||
| Guardant Health Inc. (United States) | |||||||
| Illumina Inc. (United States) | |||||||
| Thermo Fisher Scientific Inc. (United States) | |||||||
| QIAGEN N.V. (Netherlands) | |||||||
| Exact Sciences Corporation (United States) | |||||||
| Natera Inc. (United States) | |||||||
| Agilent Technologies Inc. (United States) | |||||||
| Bio-Rad Laboratories Inc. (United States) | |||||||
| Myriad Genetics Inc. (United States). |
Industry Development/News
| Company Name | Date | Key Development |
|---|---|---|
| Twist Bioscience Corporation | Feb-24 | In February 2024, Twist Bioscience Corporation introduced a cfDNA library preparation kit designed to support liquid biopsy research workflows. The product enhances genomic sample preparation capabilities for next-generation sequencing applications, contributing to improved efficiency and accuracy in cancer research and liquid biopsy assay development. |
| Illumina | Nov-23 | In November 2023, Illumina launched an advanced liquid biopsy assay for detecting non-small-cell lung cancer, expanding its oncology diagnostics portfolio. The assay strengthens its position in blood-based cancer testing by improving access to genomic insights for research and clinical applications, supporting broader adoption of minimally invasive cancer detection approaches. |
| Delfi Diagnostics | Oct-23 | In October 2023, Delfi Diagnostics introduced its first blood-based biopsy test for lung cancer screening, expanding the availability of liquid biopsy tools for early cancer detection. The launch strengthens its position in non-invasive oncology diagnostics by adding a new screening modality to existing blood-based cancer detection approaches. |
| Menarini Silicon Biosystems | Jul-23 | In July 2023, Menarini Silicon Biosystems launched the CellSearch CTC test incorporating the DLL3 biomarker for small cell lung cancer applications. The development expands its liquid biopsy assay portfolio and supports more targeted cancer diagnostics by improving circulating tumor cell analysis for treatment guidance in lung cancer cases. |
| Guardant Health, Inc. | May-22 | In May 2022, Guardant Health expanded its blood-based cancer testing services in Europe through operational deployment at the Vall d’Hebron Institute of Oncology liquid biopsy facility in Barcelona. The development strengthens access to liquid biopsy diagnostics in clinical research environments and supports broader adoption of blood-based oncology testing in European healthcare settings. |
Customize Your Report
Explore examples of how this report can be tailored to different research needs, including custom segments, additional topics or chapters, and related reports. Click a section of the wheel or its numbered marker to explore the available options.
Lung Cancer Liquid Biopsy Market — Custom Segments
| Segment | Sub-Segment |
|---|---|
| Cancer Stage | Early-Stage Lung Cancer, Locally Advanced Lung Cancer, Metastatic Lung Cancer, Post-Treatment Surveillance |
| Reimbursement Status | Fully Reimbursed, Partially Reimbursed, Self-Pay & Out-of-Pocket |
| Diagnostic Workflow | Standalone Liquid Biopsy Testing, Liquid Biopsy With Tissue Biopsy, Liquid Biopsy for Tissue Insufficiency, Serial Liquid Biopsy Monitoring |
Lung Cancer Liquid Biopsy Market — Custom TOC
| Custom Chapter | Custom Details |
|---|---|
| Clinical Adoption Pathway Assessment |
|
| Biomarker Application Opportunity Analysis |
|
| Companion Diagnostics Opportunity Evaluation |
|
Need a different cut of the data?
Request Custom ResearchWhat is the current size of the lung cancer liquid biopsy market?
How is the lung cancer liquid biopsy industry size expected to evolve during the forecast period?
How is blood-based sampling shaping routine testing and monitoring workflows in the lung cancer liquid biopsy market?
How is multi-gene NGS testing influencing clinical decision-making in the lung cancer liquid biopsy market?
Why are blood sample-based tests the leading sample type in the lung cancer liquid biopsy market?
Why is Multi-gene-parallel Analysis (NGS) the fastest-growing technology in the lung cancer liquid biopsy market?
Why is North America the largest market for lung cancer liquid biopsy?
What is accelerating lung cancer liquid biopsy adoption in Asia Pacific?
Who are the leading players in the lung cancer liquid biopsy landscape?
Our Clients
"The team took the time to understand our specific business needs and delivered a report that was well aligned with our objectives. Their expertise and understanding of the industry were clearly reflected in the quality and relevance of the insights provided."
Siemens Healthcare
"Our experience in acquiring the research report has been excellent. The depth of analysis, and actionable insights provided have been extremely valuable in supporting our ongoing R&D efforts."
GC Biopharma
"The report offered a comprehensive view of the market trends. The in-depth segmentation and analysis of emerging opportunities gave us a better understanding of the market."
Medtronic
Our Research Team & Methodology
Every Fundamental Business Insights report is built by a dedicated vertical research team, validated through a structured primary-and-secondary methodology, and reviewed for accuracy before it reaches you.
Research Team Overview
Prepared by the Healthcare & Medical Devices Research Team
Delivery
Published
Demand
Available
Support
Trust & Compliance
Research Domains
10 coverage areasResearch Intelligence
| Source | Reference |
|---|---|
| World Health Organization (WHO) | www.who.int |
| U.S. Food & Drug Administration (FDA) | www.fda.gov |
| European Medicines Agency (EMA) | www.ema.europa.eu |
| Centers for Disease Control and Prevention (CDC) | www.cdc.gov |
| National Institutes of Health (NIH) | www.nih.gov |
| National Center for Biotechnology Information (NCBI) | www.ncbi.nlm.nih.gov |
| PubMed | pubmed.ncbi.nlm.nih.gov |
| ClinicalTrials.gov | clinicaltrials.gov |
| International Organization for Standardization (ISO) | www.iso.org |
| ASTM International | www.astm.org |
| Advanced Medical Technology Association (AdvaMed) | www.advamed.org |
| Medical Device Innovation Consortium (MDIC) | mdic.org |
| Biotechnology Innovation Organization (BIO) | www.bio.org |
| International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) | www.ifpma.org |
| U.S. Pharmacopeia (USP) | www.usp.org |
| European Directorate for the Quality of Medicines & HealthCare (EDQM) | www.edqm.eu |
| World Organisation for Animal Health (WOAH) | www.woah.org |
| American Hospital Association (AHA) | www.aha.org |
| OECD Health | www.oecd.org/health |
| World Bank Data | data.worldbank.org |
Research Workflow & Quality Assurance
Data Collection
Verified information gathered through primary and secondary research.
Data Triangulation
Cross-validation using multiple independent data sources.
Forecast Modelling
Market estimates developed using historical trends and analytical models.
Analyst Validation
Findings reviewed by domain experts for accuracy and consistency.
Editorial & Quality Review
Final editorial, quality, and compliance checks before publication.
Final Publication
Released after successful completion of the internal review process.
Report Coverage
📊 Market Assessment
- Market Size & Forecast
- Market Segmentation
- Regional Analysis
- Growth Drivers & Challenges
- Market Dynamics
🏢 Competitive Intelligence
- Competitive Landscape
- Company Profiles
- Competitive Benchmarking
- Mergers & Acquisitions
- Market Share Analysis or Key Company Strategies
🔍 Strategic Analysis
- Value Chain Analysis
- Porter's Five Forces
- PESTLE Analysis
- Pricing Trends
- Supply-Demand Analysis
🚀 Future Outlook
- Technology Landscape
- Regulatory Landscape
- Investment & Funding Landscape
- Emerging Opportunities
- Future Market Outlook
Have a question about this report or need a custom scope?
Request Customization